Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
FiercePharma13h
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
NJBIZ8h
Bristol Myers Squibb kicks off $2B cost-cutting campaign
The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.
BioSpace10h
BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
Bristol Myers expects to deliver additional ~$2B in cost savings by 2027-end
Squibb is expanding its existing strategic productivity initiative to include approximately $2B in additional annualized ...
Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute
Yahoo Finance Anchor Josh Lipton recaps the top stories on Wall Street as part of today's Market Minute. US stocks (^DJI, ...
BioPharma Dive7h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...